A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Neratinib In Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 May 2012
At a glance
- Drugs Neratinib (Primary)
- Indications Breast cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- 11 May 2012 Company (Puma Biotechnology) added to associations field as reported by ClinicalTrials.gov record.
- 22 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.